Gefitinib efficacy associated with multiple expression of HER family in non-small cell lung cancer

Anticancer Research

Volumn 26, Issue 5 B, 2006, Pages 3761-3765

  Nishio, Makoto ^a   Taguchi, Fumiko ^a   Ohyanagi, Fumiyoshi ^a   Horikike, Atushi ^a   Ishikawa, Yuichi ^b   Satoh, Yukitoshi ^a   Okumura, Sakae ^a   Nakagawa, Ken ^a   Nishio, Kazuto ^c   Horai, Takeshi ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b CANCER INSTITUTE   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

EGFR mutation; Gefitinib; HER2; Molecular target agent; NSCLC; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GEFITINIB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEMOGRAPHY; DRUG EFFICACY; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UNIVARIATE ANALYSIS;

AGED; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DNA PRIMERS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; QUINAZOLINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 33750723108     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Wakeling AE, Guy SP, Woodburn JR et al: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62: 5749-5754, 2002.
2. Ranson M, Hammond LA, Ferry D et al: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20: 2240-2250, 2002.
3. Herbst RS, Maddox AM, Rothenberg ML et al: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20: 3815-3825, 2002.
4. Baselga J, Rischin D, Ranson M et al: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20: 4292-4302, 2002.
5. Fukuoka M, Yano S, Giaccone G et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237-2246, 2003.
6. Nakagawa K, Tamura T, Negoro S et al: Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ("Iressa*, ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14: 922-930, 2003.
7. Kris MG, Natale RB, Herbst RS et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Jama 290: 2149-2158, 2003.
8. Cappuzzo F, Gregorc V, Rossi E et al: Gefitinib in pretreated non-small-cell lung cancer (NSCLC): Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21: 2658-2663, 2003.
9. Cortes-Funes H and Soto Parra H: Extensive experience of disease control with gefitinib and the role of prognostic markers. Br J Cancer 89 Suppl 2: S3-8, 2003.
10. Santoro A, Cavina R, Latteri F et al: Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. Ann Oncol 15: 33-37, 2004.
11. Lynch TJ, Bell DW, Sordella R et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
12. Paez JG, Janne PA, Lee JC et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
13. Pao W, Miller V, Zakowski M et al: EGF receptor gene mutations are common in lung cancers from "never smokers* and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004.
14. Moasser MM, Basso A, Averbuch SD and Rosen N: The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61: 7184-7188, 2001.
15. Anido J, Matar P, Albanell J et al: ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9: 1274-1283, 2003.
16. WHO: World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization. WHO offset publication. pp. 48, 1979.
17. Kaplan E and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1985.
18. Miller VA, Kris MG, Shah N et al: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22: 1103-1109, 2004.
19. Marchetti A, Martella C, Felicioni L et al: EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23: 857-865, 2005.
20. Perez-Soler R, Chachoua A, Huberman M et al: A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced EGFR-expressing, non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20: 310a, 2001.
21. Barily L, Kris M, Wolf M et al: Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ("Iressa", ZD1839) monotherapy for pretreated advanced non-small cell lung cacner: IDEAL 1 and 2. Proc Am Assoc Cancer Res 44: 1362 (abstract LB-1170), 2004.
22. Hirata A, Hosoi F, Miyagawa M et al: HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res 65: 4253-4260, 2005.
23. Kosaka T, Yatabe Y, Endoh H et al: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919-8923, 2004.
24. Sasaki H, Endo K, Konishi A et al: EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res 11: 2924-2929, 2005.
25. Pao W and Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23: 2556-2568, 2005.